Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After=2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study

被引：0

作者：

Schuster, Stephen J. ^{[1
]}

Sehn, Laurie H. ^{[2
]}

Bartlett, Nancy L. ^{[3
]}

Matasar, Matthew ^{[4
]}

Assouline, Sarit ^{[5
]}

Giri, Pratyush ^{[6
]}

Kuruvilla, John ^{[7
]}

Shadman, Mazyar ^{[8
,9
]}

Cheah, Chan Y. ^{[10
,11
]}

Dietrich, Sascha ^{[12
]}

Fay, Keith ^{[13
,14
]}

Ku, Matthew ^{[15
]}

Nastoupil, Loretta ^{[16
]}

Wei, Michael C. ^{[17
]}

Yin, Shen ^{[17
]}

To, Iris ^{[17
]}

Huang, Jiangeng ^{[17
]}

Kwan, Antonia ^{[17
]}

Penuel, Elicia ^{[17
]}

Budde, L. Elizabeth ^{[18
]}

机构：

[1] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA

[2] Univ British Columbia, BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[3] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA

[4] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[5] Jewish Gen Hosp, Montreal, PQ, Canada

[6] Royal Adelaide Hosp, Adelaide, Australia

[7] Princess Margaret Canc Ctr, Toronto, ON, Canada

[8] Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[9] Univ Washington, Seattle, WA USA

[10] Sir Charles Gairdner Hosp, Linear Clin Res, Nedlands, Australia

[11] Univ Western Australia, Perth, Australia

[12] Heidelberg Univ, Heidelberg, Germany

[13] St Vincents Hosp, Sydney, Australia

[14] Royal North Shore Hosp, Sydney, Australia

[15] Univ Melbourne, St Vincents Hosp, Melbourne, Australia

[16] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[17] Genentech Inc, South San Francisco, CA USA

[18] City Hope Natl Med Ctr, Duarte, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

IBCL; non-Hodgkin lymphoma; indolent lymphoma; follicular lymphoma; bispecific antibody;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IBCL-335

引用

页码：S497 / S497

页数：1

共 12 条

[1] Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study
Bartlett, Nancy L.
Sehn, Laurie H.
Matasar, Matthew
Schuster, Stephen J.
Assouline, Sarit
Giri, Pratyush
Kuruvilla, John
Canales, Miguel
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta
Wei, Michael C.
Yin, Shen
To, Iris
Huang, Huang
Min, Juliana
Bolen, Christopher R.
Penuel, Elicia
Budde, L. Elizabeth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S453 - S453
[2] Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow-Up
Schuster, Stephen J.
Fowler, Nathan Hale
Dickinson, Michael
Martinez-Lopez, Joaquin
Kolstad, Arne
Butler, Jason
Ghosh, Monalisa
Popplewell, Leslie
Chavez, Julio C.
Bachy, Emmanuel
Kato, Koji
Harigae, Hideo
Kersten, Marie Jose
Andreadis, Charalambos
Riedell, Peter A.
Ho, P. Joy
Perez-Simon, Jose Antonio
Chen, Andy I.
Nastoupil, Loretta J.
von Tresckow, Bastian
Ferreri, Andres Jose Maria
Teshima, Takanori
Patten, Piers E. M.
McGuirk, Joseph P.
Petzer, Andreas L.
Offner, Fritz
Viardot, Andreas
Zinzani, Pier Luigi
Malladi, Ram
Zia, Aiesha
Awasthi, Rakesh
Paule, Ines
Germano, Davide
Ramos, Roberto
Hsu, Pei
Thieblemont, Catherine
Dreyling, Martin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S495 - S496
[3] Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received.2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study
Budde, Elizabeth L.
Sehn, Laurie H.
Matasar, Matthew
Schuster, Stephen J.
Assouline, Sarit
Giri, Pratyush
Kuruvilla, John
Canales, Miguel
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta
Wei, Michael C.
Yin, Shen
Doral, Michelle Y.
Li, Chi-Chung
Huang, Huang
Negricea, Raluca
Penuel, Elicia
O'Hear, Carol
Bartlett, Nancy L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S387 - S387
[4] Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study
Budde, Lihua E.
Assouline, Sarit
Sehn, Laurie H.
Schuster, Stephen J.
Yoon, Sung-Soo
Yoon, Dok Hyun
Matasar, Matthew J.
Bosch, Francesc
Kim, Won Seog
Nastoupil, Loretta J.
Flinn, Ian W.
Shadman, Mazyar
Diefenbach, Catherine
Cheah, Chan Yoon
Ma, Connie Y.
Huang, Huang
Kwan, Antonia
Wei, Michael C.
Yin, Shen
Bartlett, Nancy L.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (19) : 2250 - 2256
[5] Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study
Dickinson, Michael
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Corradini, Paolo
Iacoboni, Gloria
Khan, Cyrus
Wrobel, Thomasz
Offner, Fritz
Trneny, Marek
Wu, Shang-Ju
Cartron, Guillaume
Hertzberg, Mark
Sureda, Anna
Perez-Callejo, David
Lundberg, Linda
Relf, James
Clark, Emma
Humphrey, Kathryn
Hutchings, Martin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S435 - S435
[6] Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial
Mehta, Amitkumar
Popplewell, Leslie
Collins, Graham P.
Smith, Sonali M.
Flinn, Ian W.
Bartlett, Nancy L.
Ghosh, Nilanjan
Hacohen-Kleiman, Gal
Huo, Yanan
Su-Feher, Linda
Renard, Camille
Advani, Ranjana
Roschewski, Mark
BLOOD ADVANCES, 2024, 8 (22) : 5855 - 5863
[7] A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up
Bari, Alessia
Marcheselli, Raffaella
Marcheselli, Luigi
Alvarez, Isabel
Pozzi, Samantha
Ferri, Paola
Lazzaro, Antonio
Fragasso, Alberto
Neri, Santo
Baldini, Luca
Carella, Angelo Michele
Angrilli, Francesco
Guariglia, Roberto
Buda, Gabriele
Stelitano, Caterina
Sacchi, Stefano
ACTA HAEMATOLOGICA, 2017, 137 (01) : 7 - 14
[8] Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume
Hutchings, Martin
Carlo-Stella, Carmelo
Morschhauser, Franck
Falchi, Lorenzo
Bachy, Emmanuel
Cartron, Guillaume
Khan, Cyrus
Tani, Monica
Martinez-Lopez, Joaquin
Bartlett, Nancy L.
Salar, Antonio
Brody, Joshua
Leppa, Sirpa
Baumlin, Pauline
Mulvihill, Estefania
Relf, James
Xie, Yuying
Kaufman, Derrick
Lundberg, Linda
Dickinson, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S473 - S473
[9] Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial
Thieblemont, Catherine
Karimi, Yasmin H.
Ghesquieres, Herve
Cheah, Chan Y.
Clausen, Michael Roost
Cunningham, David
Jurczak, Wojciech
Do, Young Rok
Gasiorowski, Robin
Lewis, David John
Kim, Tae Min
van der Poel, Marjolein
Poon, Michelle Limei
Feldman, Tatyana
Linton, Kim M.
Sureda, Anna
Hutchings, Martin
Dinh, Minh H.
Kilavuz, Nurgul
Soong, David
Mark, Thomas
Sacchi, Mariana
Phillips, Tycel
Lugtenburg, Pieternella J.
LEUKEMIA, 2024, : 2653 - 2662
[10] Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial
Karimi, Yasmin
Ghesquieres, Herve
Jurczak, Wojciech
Cheah, Chan Y.
Clausen, Michael Roost
Lugtenburg, Pieternella
Cunningham, David
Do, Young Rok
Lewis, David John
Gasiorowski, Robin
Kim, Tae Min
van der Poel, Marjolein
Poon, Michelle Limei
Feldman, Tatyana
Linton, Kim M.
Sureda, Anna
Hutchings, Martin
Stirner, Mariana Cota
Liu, Yan
Kilavuz, Nurgul
Sacchi, Mariana
Thieblemont, Catherine
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S438 - S438

← 1 2 →